43
total announcements
500672.BO · 15 min delayed
Key Stats · Yahoo Finance · as of 04 Oct 2026
Market Cap
₹4,837 Cr
P/E (TTM)
49.5
EPS (TTM)
₹39.55
52W Low
₹750.00
52W High
₹2,588.00
Dividend Yield
1.47%
Beta
0.32
Price / Book
5.9
Debt / Equity
0.4
Revenue (TTM)
₹371 Cr
Gross Margin
44.07%
Operating Margin
33.22%
Novartis India Ltd
Novartis India Ltd has released its Business Responsibility and Sustainability Report (BRSR) for FY 2025-26, detailing its environmental, social, and governance initiatives.
Novartis India Ltd
Novartis India Ltd has announced the notice to its members for the 78th Annual General Meeting (AGM) to be held on September 24, 2026, through video conferencing.
Novartis India Ltd
The Board of Directors of Novartis India Limited approved changes to the company's Memorandum of Association, name, and Articles of Association, subject to shareholder approval at the upcoming Annual General Meeting.
Novartis India Ltd
Novartis India Ltd's board meeting outcome: adoption of new Articles of Association, Employee Stock Option Plan 2026, termination of Distribution and Promotion Agreement with Dr. Reddy's Laboratories, and notice of 78th Annual General Meeting.
Novartis India Ltd
Novartis India Ltd has been acquired by ChrysCapital, a private equity firm, with a 70.68% stake. Dr. Vikas Gupta has been appointed as the Managing Director and Chief Executive Officer of the organization.
Novartis India Ltd
Novartis India Ltd has completed the sale of 17,450,680 equity shares to WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners. The company's board has approved the execution of various business agreements, including a Tegrital brand license deed, a distribution agreement, and a trademark assignment and license deed. The board has also approved the appointment of new key managerial personnel, including Dr. Vikas Gupta as Managing Director and Chief Executive Officer, and Mr. Bhagwat Singh Deora as Chief Financial Officer.
Novartis India Ltd
Novartis India Ltd's board of directors held its 246th meeting on July 29, 2026, and reconstituted its Audit Committee, Nomination and Remuneration Committee, and Corporate Social Responsibility Committee due to director appointments and resignations.
Novartis India Ltd
Novartis India Ltd's Board of Directors took note of the resignation of Mr. Christopher David Snook as Chairman and the completion of the sale of 17,450,680 equity shares from Novartis AG to WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners. The Board also reclassified Novartis AG from the 'promoter' category to 'public' category and appointed new directors.
Novartis India Ltd
Novartis India Ltd's board of directors has taken note of the resignation of certain directors and the completion of the sale of 17,450,680 equity shares by Novartis AG to WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners. The sale has resulted in Novartis AG ceasing to be in control of the company and being reclassified from a promoter to a public category. The board has also appointed new directors, including additional non-executive and independent directors.
Novartis India Ltd
Novartis India Ltd's Board of Directors has taken note of the completion of the sale of 17,450,680 equity shares by Novartis AG to WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners. The Board has also reclassified Novartis AG from the 'promoter' category to 'public' category and appointed new directors to the Board.
Novartis India Ltd
Novartis India Ltd's Board of Directors approved a change in control of the company, with Novartis AG ceasing to be in control and WaveRise Investments Limited and ChrysCapital Fund X acquiring control. The company's promoter status has been reclassified, and new directors have been appointed to the Board.
Novartis India Ltd
Novartis India Ltd's Board of Directors has approved the cessation of existing directors, effective July 29, 2026. The Board noted the completion of an open offer by WaveRise Investments Limited and ChrysCapital Fund X, resulting in the acquisition of control by WaveRise and Fund X. Novartis AG has ceased to be in control of the Company and has been reclassified from the 'promoter' category to 'public' category. The Board has appointed new directors, including additional non-executive and independent directors.
Novartis India Ltd
Novartis India Ltd has announced the appointment and resignation of directors, including the reclassification of Novartis AG from promoter to public category, following the completion of an open offer and the sale of shares to new investors.
Novartis India Ltd
Novartis India Ltd's promoter, Novartis AG, has sold 70.68% of the company's equity shares, ceasing to hold any equity shares and reclassifying from 'promoter' to 'public' category shareholder.
Novartis India Ltd
Novartis India Ltd has received a disclosure from Novartis AG, its erstwhile promoter, regarding the sale of 1,74,50,680 equity shares representing 70.68% of the company's share capital.
Novartis India Ltd
Novartis India Ltd has been reclassified from the 'Promoter' category to the 'Public' category after the acquisition of control by WaveRise and Fund X. The reclassification is effective from July 29, 2026, and NAG has undertaken not to take any action that could result in its reclassification as a promoter of the Company.
Novartis India Ltd
Novartis India Ltd's Board of Directors approved the completion of Open Offer and sale of 17,450,680 equity shares from Novartis AG to WaveRise Investments Limited, ChrysCapital Fund X, and Two Infinity Partners. The Board also reclassified Novartis AG from the 'promoter' category to 'public' category due to change in control. Additionally, three new directors were appointed to the Board.
Novartis India Ltd
Novartis India Ltd has received a disclosure under Regulation 29(1) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011, indicating that WaveRise Investments Ltd, ChrysCapital Fund X, and Two Infinity Partners have acquired a significant stake in the company, with Acquirer 3 holding 40% of the shares before the acquisition and Acquirer 3, Acquirer 2, and Acquirer 1 holding 56.45%, 10.32%, and 3.91% of the shares after the acquisition, respectively.
Novartis India Ltd
Novartis India Ltd has announced the publication of unaudited financial results for the quarter ended June 30, 2026, as per Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Novartis India Ltd
Novartis India Ltd has submitted its unaudited financial results for the quarter ended June 30, 2026, along with a limited review report from its statutory auditors.